Literature DB >> 6495255

Intra-platelet platelet factor 4 (IP.PF4) and the heparin-mobilisable pool of PF4 in health and atherosclerosis.

J R O'Brien, M D Etherington, M Pashley.   

Abstract

Some patients with clinical evidence of atherosclerosis and others with diabetes were compared with appropriate controls. The intraplatelet level of platelet factor 4 (PF4) was significantly decreased in the arteriopaths and was lower in the diabetics when compared with controls. Patients with transient ischaemic attacks and stroke have even lower values. Intravenous heparin liberates large amounts of PF4 from an unknown reservoir, perhaps the endothelium, into the plasma. Arteriopaths liberated significantly more PF4 than the controls and the diabetics most. If a second heparin injection is given 24 hr after the first, the resultant plasma PF4 level was on average half that achieved after the first injection and again the patients had higher levels than the controls. Thus the reservoir originally "emptied" of PF4 by the heparin had been partially refilled in 24 hr and the reservoir in the atherosclerotic patients then contained more than the controls. Patients with atherosclerosis and especially diabetics differ from controls in the PF4 content of their platelets and in their response to heparin and in the rate of refill of the "heparin-mobilisable pool of PF4".

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6495255

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Platelet factor 4 (PF4) in septicaemia.

Authors:  R Lorenz; M Brauer
Journal:  Infection       Date:  1988 Sep-Oct       Impact factor: 3.553

2.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

3.  Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients.

Authors:  Jos P J Wester; Fred J L M Haas; Douwe H Biesma; J A Leusink; Gerda Veth
Journal:  Intensive Care Med       Date:  2004-05-20       Impact factor: 17.440

Review 4.  Platelet chemokines in vascular disease.

Authors:  Christian A Gleissner; Philipp von Hundelshausen; Klaus Ley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-08-21       Impact factor: 8.311

Review 5.  Platelets and their chemokines in atherosclerosis-clinical applications.

Authors:  Philipp von Hundelshausen; Martin M N Schmitt
Journal:  Front Physiol       Date:  2014-08-08       Impact factor: 4.566

Review 6.  Targeting Platelet in Atherosclerosis Plaque Formation: Current Knowledge and Future Perspectives.

Authors:  Lei Wang; Chaojun Tang
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

7.  Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.

Authors:  M Margaret Prechel; Jeanine M Walenga
Journal:  Thromb J       Date:  2013-04-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.